New drug shows promise in stopping prostate cancer spread to bone

A recent study at the University of Michigan has found a new drug, known as Cabozantinib, designed to target mainly two important pathways linked to the growth and spread of prostate cancer is showing promise to kill tumors that have spread to the bone.

After treatment, men in trial with metastatic prostate cancer reported some tumor regressions in areas of spread outside the bone. The regression was accompanied by improvement in bone pain and decreased need for narcotic use

The findings were presented at the American Society of Clinical Oncology annual meeting.